A phase I study of single i. v. doses of a new sugar containing nitrosourea 6-deoxy-3,5 di-O-methyl 6-(3 methyl-3-nitrosoureido)-alpha-D-glucofuranoside (CGP 6809, EDMN) has been carried out in 47 patients with advanced solid tumors. Nine dose levels between 200 and 4500 mg/m2 were examined. Nausea and vomiting were seen in most patients but were controlled with antiemetics. Myelosuppression was minimal. The dose-limiting toxicity was hepatotoxicity, occurring early (peak at days 2–4) and resolving rapidly. No cumulative toxicity was seen with an every 6 weeks schedule. Other toxicities were abdominal pain, diarrhea, arm pain, restlessness, and headache. Pharmacokinetic studies in 20 patients using an HPLC assay and in 5 patients using [14C]EDMN showed a short half-life, rapid plasma clearance, rapid metabolism, and minimal excretion of unchanged drug. There was one partial response in a patient with colon carcinoma. The recommended dose for phase II studies is 3750 mg/m2 every 6 weeks.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bernacki RJ, Wilson GL, Mossman BT, Angelino N, Kanter PM, Korytnyk W (1985) Therapeutic and diabetogenic potential of two newly synthesized nitrosoureido sugars. Cancer Res 45: 695–702
Brown MB, Engleman L, France JW, Hill MA, Jenrich RI, Toporce JD (1981) BMDP statistical software. University of California, Los Angeles
Cowens JW (1984) Preclinical pharmacology of ethyl 6-deoxy-3,6 di-O-methyl-6-(3 methyl-3 nitrosoureido)-α-D-glucofuranoside (CGP 6809) in the rat. Proc AACR 25: 292
Cowens JW, Pendyala L, Madajewicz S, Creaven P (1985) Pharmacokinetics of ethyl 6-deoxy-3,6 di-O-methyl-6-(3-methyl-3-nitrosoureido)-α-D-glucofuranoside (CGP 6809). Proc ASCO 4: 47
Creaven PJ, Plager JE, Cowens JW, Madajewicz S, Pendyala L, Mittelman A, Petrelli N, Herrera L, Karakousis C, Razack M, Takita H, Huben R, Cushman K (1986) Phase I trial of ethyl 6-deoxy-3,5-di-O-methyl-6-(3-methyl-3-nitrosoureido)-α-D-glucofuranoside (CGP 6809 EDMN). Proc Am Soc Clin Oncol 5: 36 (141)
Kanter PM, Pavelic Z, Bullard GA (1983) Preclinical pharmacological study of CGP 6809: report on therapeutic and toxicological effects. IND application to U. S. Food and Drug Administration
Schieweck K, Stanek J, Schmidt-Ruppin H (1982) Effects of a new nitrosoureido-sugar derivative, CGP 6809. Proceedings of the 13th International cancer Congress, p 385
About this article
Cite this article
Creaven, P.J., Madajewicz, S., Cowens, J.W. et al. Phase I clinical trial of ethyl 6-deoxy-3,5-di-O-methyl 6-(3 methyl-3-nitrosoureido)-alpha-D-glucofuranoside (CGP 6809). Cancer Chemother. Pharmacol. 20, 37–40 (1987). https://doi.org/10.1007/BF00252957
- Abdominal Pain
- Partial Response